Alerts will be sent to your verified email
Verify Email
MARKSANS
|
Marksans Pharma
|
Strides Pharma Scien
|
FDC
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
25.0 . | 230.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
13.0 . | 215.0 . | n/a |
|
R&D as a % of Total Sales
|
2.0 % | 1.84 % | 2.22 % |
|
Financials
|
|||
|
5 yr Average ROE
|
17.57 % | 23.7 % | 12.9 % |
|
5yr average Equity Multiplier
|
1.33 | 2.62 | 1.57 |
|
5yr Average Asset Turnover Ratio
|
0.9 | 0.6 | 0.55 |
|
5yr Avg Net Profit Margin
|
14.56 % | 12.9 % | 15.2 % |
|
Price to Book
|
3.43 | 3.22 | 3.19 |
|
P/E
|
24.17 | 22.33 | 27.08 |
|
5yr Avg Cash Conversion Cycle
|
71.65 Days | -51.45 Days | -13.89 Days |
|
Inventory Days
|
89.77 Days | 69.05 Days | 61.89 Days |
|
Days Receivable
|
65.99 Days | 60.35 Days | 18.98 Days |
|
Days Payable
|
88.81 Days | 225.58 Days | 89.17 Days |
|
5yr Average Interest Coverage Ratio
|
38.03 | 0.72 | 90.41 |
|
5yr Avg ROCE
|
21.95 % | 10.5 % | 13.8 % |
|
5yr Avg Operating Profit Margin
|
20.32 % | 12.17 % | 17.7 % |
|
5 yr average Debt to Equity
|
0.02 | 1.01 | 0.0 |
|
5yr CAGR Net Profit
|
10.03 % | 68.01 % | -2.41 % |
|
5yr Average Return on Assets
|
13.19 % | 10.97 % | 8.22 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
43.87 % | 27.86 % | 69.66 % |
|
Share Pledged by Promoters
|
0.0 | 44.13 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-4.73 % | -3.21 % | 0.17 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.97 % | 0.16 % | 0.03 % |
|
Marksans Pharma
|
Strides Pharma Scien
|
FDC
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Customer Segment
|
Customer Segment
|
Customer Segment
|
-
|